Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.8%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price was down 5.8% during mid-day trading on Tuesday . The stock traded as low as $27.11 and last traded at $27.20. Approximately 120,658 shares were traded during mid-day trading, a decline of 36% from the average daily volume of 189,764 shares. The stock had previously closed at $28.87.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on DNTH shares. Jefferies Financial Group increased their price target on Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a report on Friday, March 22nd. Lifesci Capital upgraded Dianthus Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th. Raymond James increased their price objective on Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a report on Thursday, April 18th. Cantor Fitzgerald assumed coverage on Dianthus Therapeutics in a report on Thursday, June 27th. They set an “overweight” rating for the company. Finally, Wedbush increased their price objective on Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $42.83.

Dianthus Therapeutics Price Performance

The company has a market capitalization of $793.92 million, a price-to-earnings ratio of -4.65 and a beta of 1.88. The stock has a 50-day moving average price of $23.88 and a 200-day moving average price of $21.80.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The firm had revenue of $0.87 million during the quarter, compared to the consensus estimate of $0.48 million. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.18 earnings per share for the current year.

Institutional Trading of Dianthus Therapeutics

Several hedge funds have recently added to or reduced their stakes in DNTH. Tower Research Capital LLC TRC acquired a new stake in Dianthus Therapeutics during the 4th quarter worth approximately $25,000. Citigroup Inc. acquired a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $53,000. Virtu Financial LLC acquired a new stake in Dianthus Therapeutics during the 1st quarter worth approximately $390,000. Laurion Capital Management LP acquired a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $497,000. Finally, Hussman Strategic Advisors Inc. acquired a new position in Dianthus Therapeutics in the 1st quarter valued at $630,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.